Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company trimmed its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 4.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 142,040 shares of the biotechnology company’s stock after selling 7,116 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.11% of Arrowhead Pharmaceuticals worth $2,751,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. SG Americas Securities LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 27.4% in the second quarter. SG Americas Securities LLC now owns 9,369 shares of the biotechnology company’s stock valued at $244,000 after buying an additional 2,014 shares during the last quarter. Fifth Third Bancorp raised its position in Arrowhead Pharmaceuticals by 42.5% during the 2nd quarter. Fifth Third Bancorp now owns 1,186 shares of the biotechnology company’s stock worth $31,000 after buying an additional 354 shares during the last quarter. EFG Asset Management North America Corp. lifted its stake in shares of Arrowhead Pharmaceuticals by 86.8% in the 2nd quarter. EFG Asset Management North America Corp. now owns 51,828 shares of the biotechnology company’s stock worth $1,346,000 after acquiring an additional 24,083 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Arrowhead Pharmaceuticals by 2.9% in the second quarter. Bank of New York Mellon Corp now owns 1,085,069 shares of the biotechnology company’s stock valued at $28,201,000 after acquiring an additional 30,086 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Arrowhead Pharmaceuticals by 20.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 28,739 shares of the biotechnology company’s stock worth $747,000 after acquiring an additional 4,927 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $23.61 on Monday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $17.05 and a 12-month high of $39.83. The stock has a market cap of $2.94 billion, a P/E ratio of -4.70 and a beta of 0.91. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06. The company has a 50-day moving average of $20.61 and a two-hundred day moving average of $23.19.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on ARWR shares. B. Riley reaffirmed a “buy” rating and issued a $55.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 12th. Citigroup decreased their price target on Arrowhead Pharmaceuticals from $27.00 to $26.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 27th. Sanford C. Bernstein cut their price objective on Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. StockNews.com upgraded shares of Arrowhead Pharmaceuticals to a “sell” rating in a research report on Wednesday, November 27th. Finally, Chardan Capital reiterated a “buy” rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $42.70.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.